A Win For Aclaris Therapeutics, Inc.
Tue, Jan 20, 2026 at 07:15 PM
Aclaris Therapeutics, Inc. (ACRS:NASDAQ) shot up at $4.43, representing a gain of 69.1%. On Tue, Jan 20, 2026, ACRS:NASDAQ touched a New 2-Week High of $4.43. The stock appeared on our News Catalysts scanner on Fri, Jan 16, 2026 at 02:18 AM in the 'MISCELLANEOUS' category. From Tue, Jan 06, 2026, the stock recorded 55.56% Up Days and 60.00% Green Days
About Aclaris Therapeutics, Inc. (ACRS:NASDAQ)
Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology.
Top 10 Gainers:
- INVO Fertility, Inc. (IVF:NASDAQ), 191.73%
- Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ), 165.96%
- Pheton Holdings Ltd (PTHL:NASDAQ), 105.16%
- Aclaris Therapeutics, Inc. (ACRS:NASDAQ), 69.08%
- RAPT Therapeutics, Inc. (RAPT:NASDAQ), 64.02%
- Signing Day Sports, Inc. (SGN:NYSEMKT), 61%
- Youlife Group Inc. (YOUL:NASDAQ), 59.93%
- Top Wealth Group Holding Limited (TWG:NASDAQ), 54.31%
- Lulu's Fashion Lounge Holdings, Inc. (LVLU:NASDAQ), 42.28%
- Lottery.com Inc. (SEGG:NASDAQ), 42.19%